Objective: The objective of this review was to update evidence‐based medicine
recommendations for treating motor symptoms of Parkinson's disease (PD). Background …

Purinergic signalling, ie, the role of nucleotides as extracellular signalling molecules, was
proposed in 1972. However, this concept was not well accepted until the early 1990's when …

After more than two decades of preclinical and clinical studies, on August 27, 2019, the US
Food and Drug Administration (FDA) approved the adenosine A 2A receptor antagonist …

The adenosine modulation system mostly operates through inhibitory A1 (A1R) and
facilitatory A2A receptors (A2AR) in the brain. The activity‐dependent release of adenosine …

The motor features of Parkinson's disease (PD) are well known to manifest only when striatal
dopaminergic deficit reaches 60–70%. Thus, PD has a long pre-symptomatic and pre-motor …

Adenosine is an endogenous purine-based nucleoside expressed nearly in all body tissues.
It regulates various body functions by activating four G-protein coupled receptors, A 1, A 2A …

Purinergic signalling, ie ATP as an extracellular signalling molecule and cotransmitter in
both peripheral and central neurons, is involved in the physiology of neurotransmission and …

This review is focused on the pathophysiology and therapeutic potential of purinergic
signalling. A wide range of diseases are considered, including those of the central nervous …

Abstract Adenosine A 2A receptor (A 2A R) is a G-protein coupled receptor that regulates
several important functions in the central nervous system. Large amount of preclinical data …

The structure constituted by a G protein coupled receptor (GPCR) homodimer and a G
protein provides a main functional unit and oligomeric entities can be viewed as multiples of …